#MedicalTechnology #Stock News - Electromedical Technologies (OTCQB:
$EMED) Produces
$4.2 Million in Device Inventory to Meet Demand; @ElectromedicalT
Company completes production of 1,200_FDA-cleared
WellnessPro+ devices
Inventory build completed ahead of on-boarding new medical
practitioners and distributors
Demand driven by pain sufferers desire to find non-invasive
alternatives
SCOTTSDALE, AZ, November 19, 2020 (Investorideas.com Newswire) – Breaking Medical Technology stock news - Electromedical Technologies, Inc. (OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared WellnessPro+ device, representing approximately $4.2 million of inventory to meet demand.
Read this news featuring EMED in full at https://www.investorideas.com/news/2020/biotech/11191EMED-Device-Inventory.asp
The Company began production in
September and has fully paid for and completed its first phase of inventory
buildup in order to meet rising demand as we transition into 2021. We want to
make sure that we do not run out of inventory which occurred in the first
quarter of this year.
Matthew Wolfson, Founder and
CEO of EMED, commented, “Every day more doctors and patients are realizing the
importance of using methods that will have a positive effect in reducing pain
without having negative effects on the immune system, especially in today’s
pandemic environment. The reason for the increase in demand is that more and more
people are realizing that there are other powerful treatment options such as
bioelectronics, that does not include injections, invasive procedures or
opioids that have the possibility of harmful side effects such as addiction and
death.”
Commenting further, Mr. Wolfson said, “This
inventory increase fits perfectly with our strategic plan of engaging and
onboarding hundreds of new medical practitioners and distributors. In today’s
economic environment, many people are seeking to create new revenue streams for
their families. We have a way to help thousands of people to live a better
quality of life, pain free and addiction free and at the same time provide a
real income opportunity for anyone who wishes to join our brand ambassador
team.” (https://electromedtech.com/register/)
Finally commenting, Mr. Wolfson
said, “In the world we live in today, people cannot afford the risks associated
with opioid-based drugs, but they need results. Word of mouth has been a very
valuable marketing tool because our device delivers a powerful solution to
chronic pain without any dangerous or harmful side effects. The Wellness Pro
produces real results so people can live pain free and get their lives back!”
About Electromedical Technologies
Headquartered in Scottsdale
Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared,
bioelectronic medical device manufacturing company initially focused on the
treatment of various chronic, acute, intractable, and post-operative pain
conditions. Through university collaboration agreements the company is working
to develop a comprehensive research program in defining the effects of
electro-modulation on the human body by studying the impacts of electrical
fields in cell signaling and effects on virus assembly and immune responses
with the goal of improving human wellbeing. The company’s current cleared
product indications are for chronic acute post traumatic and post-operative,
intractable pain relief.
Our animal studies do not involve
any human testing, and are not related to our current products. We are
conducting this research to augment and advance the science of
electro-modulation in healthcare. The
United States Food and Drug Administration has not reviewed or approved our animal
research studies
For more information, visit www.electromedtech.com.
Safe Harbor Statement
This release contains
forward-looking statements that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although we believe
that the expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give no assurance
or guarantee that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should,"
"could," "expect," "anticipate,"
"estimate," "believe," "intend," or
"project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are subject
to numerous factors and uncertainties, including but not limited to: adverse
economic conditions, competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate capital,
inability to carry out research, development and commercialization plans, loss
or retirement of key executives and other specific risks. To the extent that
statements in this press release are not strictly historical, including
statements as to revenue projections, business strategy, outlook, objectives,
future milestones, plans, intentions, goals, future financial conditions, events
conditioned on stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this release are subject to certain
risks and uncertainties that could cause actual results to differ materially
from the statements made.
Corporate Contact:
Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email: ceo@electromedtech.com
https://electromedtech.com
Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Contact each company directly regarding content and press release questions.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Disclosure : this
news release featuring Electromedical
Technologies, Inc. (OTCQB: EMED) is a paid for news
release on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
About Investorideas.com
https://www.investorideas.com/About/
Sign up for free stock news alerts at
Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech Stocks Directory
Get News Alerts on Biotech Stocks